256 related articles for article (PubMed ID: 28689934)
1. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization.
McDevitt JL; Alian A; Kapoor B; Bennett S; Gill A; Levitin A; Sands M; Narayanan Menon KV; Aucejo FN; Estfan B; Pillai AK; Kalva SP; McLennan G
J Vasc Interv Radiol; 2017 Oct; 28(10):1371-1377. PubMed ID: 28689934
[TBL] [Abstract][Full Text] [Related]
2. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.
Padia SA; Johnson GE; Horton KJ; Ingraham CR; Kogut MJ; Kwan S; Vaidya S; Monsky WL; Park JO; Bhattacharya R; Hippe DS; Harris WP
J Vasc Interv Radiol; 2017 Jun; 28(6):777-785.e1. PubMed ID: 28365172
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
[TBL] [Abstract][Full Text] [Related]
4. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
[TBL] [Abstract][Full Text] [Related]
5. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
[TBL] [Abstract][Full Text] [Related]
6. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
Lokken RP; Fidelman N; Kolli KP; Kerlan RK
J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
[TBL] [Abstract][Full Text] [Related]
8. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
13. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
[TBL] [Abstract][Full Text] [Related]
15. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma.
Golfieri R; Mosconi C; Cappelli A; Giampalma E; Galaverni MC; Pettinato C; Renzulli M; Monari F; Angelelli B; Pini P; Terzi E; Ascanio S; Garzillo G; Piscaglia F; Bolondi L; Trevisani F
Future Oncol; 2015; 11(23):3133-42. PubMed ID: 26467398
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
